In conclussion, the present propensity-matched analysis of NSCLC patients harboring EGFR activating mutations revealed that the utility of EGFR TKIs in the adjuvant treatment significantly improve the DFS after complete resection. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.